Oral ciprofloxacin as prophylaxis in transurethral resection of the prostate.
A new quinolone antibacterial, ciprofloxacin, was evaluated as oral prophylaxis for transurethral resection of the prostate in a randomised controlled trial. A 3-day course of perioperative ciprofloxacin 250 mg twice daily reduced the post-operative infection rate, the post-operative hospital stay and the frequency of infective complications. Ciprofloxacin was well tolerated and no significant haematological or biochemical side effects were detected.
Murdoch
D A
DA
Department of Medical Microbiology, London Hospital.
Badenoch
D F
DF
Gatchalian
E R
ER
D001437:Bacteriuria / Q000150:complications; D002939:Ciprofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D011468:Prostatectomy; D011897:Random Allocation; D013530:Surgical Wound Infection / Q000150:complications / Q000382:microbiology / Q000517:prevention & control*
D002939:Ciprofloxacin